IKT
Inhibikase TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
+
Peers tracked
11
U.S. public peers
Grade Position
In line
vs peer average
IKT vs peer average
69/100
IKT vs. peer average (B vs. C)
Grade spread
A 2 · B 2 · C 1 · D 2 · F 3
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
GOSS is the first available peer comparator.
Gossamer Bio is the closest late-stage development comparator: its official materials describe seralutinib in PAH and note Phase 3 PROSERA enrollment completion, which makes it relevant for benchmarking pivotal-study execution, readout sensitivity, and PAH-specialist investor expectations.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
IKT
Inhibikase Therapeutics
GOSS
Gossamer Bio
Grade
B
B
Momentum
84
38
Value
41
41
Sentiment
51
100
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Constructive
Constructive
Grade position vs GOSS
IKT / GOSS
Grade Position
In line
IKT vs. peer average (B vs. C)
69/100
Momentum
84
IKTValue
41
IKTSentiment
51
GOSSRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs IKT
GOSS is the first peer returned for this comparison set.